EcoDrugPlus

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSFHEG00000002981
Gene Symbol: LOC105926687
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c

Ensembl ID : ENSFHEG00000020003
Gene Symbol: LOC105916319
3 Cross references
215 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSFHEG00000006056
Gene Symbol: LOC105915485
3 Cross references
212 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-3

Ensembl ID : ENSFHEG00000017360
Gene Symbol: LOC105928608
3 Cross references
203 Possible Orthologues:

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSFHEG00000014948
Gene Symbol: LOC105939430
2 Cross references
198 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1i-Like

Ensembl ID : ENSFHEG00000012315
Gene Symbol: LOC105937061
2 Cross references
206 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSFHEG00000002422
Gene Symbol: LOC105934051
2 Cross references
193 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSFHEG00000001719
Gene Symbol: LOC105934114
3 Cross references
168 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSFHEG00000001723
Gene Symbol: LOC105934091
3 Cross references
181 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSFHEG00000001713
Gene Symbol: LOC105934089
3 Cross references
188 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSFHEG00000009791
Gene Symbol: XDH
3 Cross references
199 Possible Orthologues:

Ensembl ID : ENSFHEG00000019747
Gene Symbol: -
Cross references: -
233 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).